in

Biotechnology company: Prothena Corporation (PRTA) (2012)

Prothena Corporation plc (NASDAQ: PRTA) was founded in 2012 and is headquartered in Dún Laoghaire, Ireland. It has 96 full-time employees. It is a late-stage clinical stage biotechnology company that focuses on the treatment of protein misfolding (protein misfolding). ) Or the discovery, development and commercialization of new immunotherapies for cell adhesion diseases.

Prothena Corporation Logo

Prothena Corporation (PRTA):

Prothena Corporation plc is a clinical-stage biotechnology company focusing on the discovery, development and commercialization of new antibodies for the treatment of various protein misfolding or cell adhesion-related diseases, mainly targeting disease-caused proteins and developing therapeutic clones Antibody drugs. Candidate products include:

  1. NEOD001-a monoclonal antibody used to treat AL amyloidosis, currently in phase III clinical trials;
  2. PRX002-Phase Ib clinical trials for the treatment of Parkinson’s disease and other related synuclein diseases have been completed;
  3. PRX003-is a monoclonal antibody used to treat psoriasis and other inflammatory diseases, currently in the Ib clinical trial stage;
  4. PRX004-is a monoclonal antibody, currently in the preclinical development stage.

Prothena Corporation has signed licensing, development and commercialization agreements with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target α-synuclein.

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all Intels

The world’s largest producer of granular activated carbon: Calgon Carbon Corporation (CCC) (1942)

Canadian biopharmaceutical company: Clementia Pharmaceuticals (CMTA)-delisting (2010)